Related Experiment Videos
A double blind study on azathioprine efficacy in multiple sclerosis: final report
C Milanese1, L La Mantia, A Salmaggi
1Istituto Nazionale Neurologico C. Besta, Milan, Italy.
Journal of Neurology
|May 1, 1993
Summary
Azathioprine treatment for multiple sclerosis (MS) showed a trend towards slowing disease progression and reducing relapses over three years. This immunomodulatory therapy is suggested for managing MS symptoms.
Area of Science:
- Neurology
- Immunology
- Clinical Trials
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Current MS treatments aim to reduce inflammation and manage symptoms.
- Long-term efficacy of immunomodulatory drugs in MS requires ongoing investigation.
Purpose of the Study:
- To evaluate the efficacy of azathioprine in patients with multiple sclerosis.
- To assess the impact of azathioprine on disease progression and relapse rates.
Main Methods:
- A 3-year, double-blind study involving 40 patients with relapsing-remitting or progressive MS.
- Patients received azathioprine at a dosage of 2 mg/kg/day.
- Outcomes measured included changes on the Expanded Disability Status Scale (EDSS) and survival analysis.
Main Results:
- A trend favoring azathioprine was observed in slowing disease progression.
- Azathioprine demonstrated a trend towards reducing the frequency of MS relapses.
- Mean changes on the EDSS indicated potential benefits of the treatment.
Conclusions:
- Azathioprine shows a promising trend in managing multiple sclerosis progression and relapses.
- Findings support the use of azathioprine as a therapeutic option for MS patients.
- Further research and clinical trials reinforce the role of azathioprine in MS treatment.